Edith Cowan University

About: Edith Cowan University is a education organization based out in Perth, Western Australia, Australia. It is known for research contribution in the topics: Population & Tourism. The organization has 4040 authors who have published 13529 publications receiving 339582 citations. The organization is also known as: Edith Cowan & ECU.

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Abstract: Summary Background The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43–0·74], p Methods This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with complete resection of cutaneous melanoma metastatic to lymph node, classified as American Joint Committee on Cancer staging system, seventh edition (AJCC-7) stage IIIA (at least one lymph node metastasis >1 mm), IIIB, or IIIC (without in-transit metastasis), and with an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomly assigned (1:1) via a central interactive voice response system to receive intravenous pembrolizumab 200 mg or placebo every 3 weeks for up to 18 doses or until disease recurrence or unacceptable toxicity. Randomisation was stratified according to disease stage and region, using a minimisation technique, and clinical investigators, patients, and those collecting or analysing the data were masked to treatment assignment. The two coprimary endpoints were recurrence-free survival in the intention-to-treat (ITT) population and in patients with PD-L1-positive tumours. The secondary endpoint reported here was distant metastasis-free survival in the ITT and PD-L1-positive populations. This study is registered with ClinicalTrials.gov , NCT02362594 , and EudraCT, 2014-004944-37. Findings Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to receive either pembrolizumab (n=514) or placebo (n=505). At an overall median follow-up of 42·3 months (IQR 40·5–45·9), 3·5-year distant metastasis-free survival was higher in the pembrolizumab group than in the placebo group in the ITT population (65·3% [95% CI 60·9–69·5] in the pembrolizumab group vs 49·4% [44·8–53·8] in the placebo group; HR 0·60 [95% CI 0·49–0·73]; p Interpretation Pembrolizumab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median follow-up, which was consistent with the improvement in recurrence-free survival. Therefore, the results of this trial support the indication to use adjuvant pembrolizumab therapy in patients with resected high risk stage III cutaneous melanoma. Funding Merck Sharp & Dohme.

Global strategies for SMe‐business: applying the SMALL framework

Abstract: The World Wide Web (WWW) offers exciting new opportunities for small and medium‐sized enterprises (SMEs) to extend their customer base into the global marketplace. However, in order to exploit these advantages in a global strategy, the SME needs to adopt an entirely different approach to strategic planning and management which can enable it to deploy an extensive infrastructure network based on shared resources with other firms. This paper presents a framework for the analysis and design of global strategies within the organisational context of SMEs using Internet‐based information technologies. Central to the framework – SMALL – is the transformation of the key attributes of an SME environment through a virtual organising perspective. The framework is supported by a number of case examples of SMEs operating in a global context and a detailed analysis of three Australian SMEs. It provides a new perspective to strategies for e‐business in SMEs and to e‐business research.

Acute effect of alternating heavy and light resistances on power output during upper-body complex power training.

Abstract: This study investigated the effect on upper-body power output of manipulating resistances during contrast or complex power training. This power-training strategy typically entails the athlete alternating sets of a heavy resistance in a strength-oriented exercise with sets of lighter resistances in a power-oriented exercise. Sixteen rugby league players, who were experienced in power training and who performed complex training on a regular basis, served as subjects for this study and were divided equally into a control (Con) or experimental (Exp) group. Both groups were pre- and posttested for power output while performing explosive bench press throws in a Smith machine with a resistance of 50 kg (BT P50). The Exp group performed an intervention strategy of a 6-repetition set of bench presses with a resistance of 65% of 1 repetition maximum (65% 1RM) between tests. At the pretest occasion, no differences were observed between the groups in power output; however, at the posttesting, a significant difference in power output was observed between the groups in the BT P50. The 4.5% increase in the power output recorded during the posttesting BT P50 for the Exp group was determined to be significantly different from all other scores (p < or = 0.05). These data indicate that the performance of a set of heavy resistance strength training exercise between power training sets will acutely enhance power output in the second power training set. This effect has been previously theorized as possibly due to some combination of acute neural or mechanical adaptations.